凤凰网首页 手机凤凰网

凤凰卫视
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
  • [亚太] 上证指数 2319.12 (1.00%) 深证成指 9466.14 1.78% 恒生指数 19664.10 -1.06% 台北 7233.69 0.17% 韩国 1964.83 0.39%
  • [亚太] 日经 8841.22 -0.09% 澳大利亚 4348.48 0.45% 新西兰 3294.64 0.40% 印度孟买 17234.00 0.92% 新加坡 2916.26 0.75%
  • [美洲] 道琼斯 12660.50 -0.58% 纳斯达克 2816.55 0.40% 标普500 1316.33 -0.16% 加拿大 12466.50 0.02% 巴西 62904.20 -0.08%
  • [欧洲] 英国富时 5733.45 -1.07% 法国CAC 3318.76 -1.32% 德国DAX 6511.98 -0.43% 俄罗斯 1508.04 -0.44% Stoxx50 2436.62 -0.97%
  • [其他] 纽约原油 99.70 0.00% 纽约黄金 1738.40 0.00% 人民币/美元 6.33 0.00% 美元指数 78.83 0.00% 基金指数 3782.30 1.37%
免费注册
莱茵生物(002166)公告正文

莱茵生物:2018年第三季度报告全文

公告日期 2018-10-29
股票简称:莱茵生物 股票代码:002166
                桂林莱茵生物科技股份有限公司 2018 年第三季度报告全文




桂林莱茵生物科技股份有限公司

     2018 年第三季度报告




        2018 年 10 月




                                                                  1
                                    桂林莱茵生物科技股份有限公司 2018 年第三季度报告全文




                         第一节 重要提示


    公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真

实、准确、完整,不存在虚假记载、误导性陈述或者重大遗漏,并承担个别和

连带的法律责任。

    所有董事均已出席了审议本次季报的董事会会议。

    公司负责人秦本军、主管会计工作负责人郑辉及会计机构负责人(会计主管

人员)张为鹏声明:保证季度报告中财务报表的真实、准确、完整。




                                                                                      2
                                                              桂林莱茵生物科技股份有限公司 2018 年第三季度报告全文




                                       第二节 公司基本情况

一、主要会计数据和财务指标

公司是否需追溯调整或重述以前年度会计数据
□ 是 √ 否

                                        本报告期末                      上年度末              本报告期末比上年度末增减

总资产(元)                               2,396,978,803.64                2,896,950,513.93                       -17.26%

归属于上市公司股东的净资产(元)           1,108,848,636.16                1,050,989,341.32                         5.51%

                                                       本报告期比上年同期                              年初至报告期末比上
                                     本报告期                                     年初至报告期末
                                                              增减                                         年同期增减

营业收入(元)                       148,297,170.58                  -10.91%          455,477,822.79              -16.40%

归属于上市公司股东的净利润(元)        5,212,032.38                 -72.03%           77,478,650.45              -13.91%

归属于上市公司股东的扣除非经常
                                        3,883,101.65                 -76.18%           73,601,132.43              -13.75%
性损益的净利润(元)

经营活动产生的现金流量净额(元)       29,277,552.20                 -90.85%            9,170,852.21              -97.56%

基本每股收益(元/股)                           0.01                 -75.00%                    0.18              -14.29%

稀释每股收益(元/股)                           0.01                 -75.00%                    0.18              -14.29%

加权平均净资产收益率                          0.51%                  76.61%                   7.16%                -2.95%

非经常性损益项目和金额
√ 适用 □ 不适用
                                                                                                                  单位:元

                         项目                                 年初至报告期期末金额                       说明

非流动资产处置损益(包括已计提资产减值准备的冲销部分)                     -1,756,000.00

计入当期损益的政府补助(与企业业务密切相关,按照国家统
                                                                               7,448,730.84
一标准定额或定量享受的政府补助除外)

计入当期损益的对非金融企业收取的资金占用费                                       79,740.89

除上述各项之外的其他营业外收入和支出                                       -1,915,564.84

减:所得税影响额                                                                 -20,611.13

合计                                                                           3,877,518.02                --

对公司根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义界定的非经常性损益项目,以及把《公
开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》中列举的非经常性损益项目界定为经常性损益的项目,应
说明原因
□ 适用 √ 不适用
公司报告期不存在将根据《公开发行证券的公司信息披露解释性公告第 1 号——非经常性损益》定义、列举的非经常性损益
项目界定为经常性损益的项目的情形。

                                                                                                                            3
                                                           桂林莱茵生物科技股份有限公司 2018 年第三季度报告全文


二、报告期末股东总数及前十名股东持股情况表

1、普通股股东和表决权恢复的优先股股东数量及前 10 名股东持股情况表

                                                                                                            单位:股

                                                         报告期末表决权恢复的优先
报告期末普通股股东总数                          54,064                                                            0
                                                         股股东总数(如有)

                                            前 10 名股东持股情况

                                                                         持有有限售条          质押或冻结情况
         股东名称           股东性质    持股比例          持股数量
                                                                         件的股份数量     股份状态        数量

秦本军                    境内自然人          17.57%        76,840,512       57,630,384 质押              45,820,000

姚新德                    境内自然人           7.86%        34,361,643       25,771,232 质押              34,361,425

梁定志                    境内自然人           4.77%        20,874,447

中央汇金资产管理有限
                          国有法人             4.46%        19,491,600
责任公司

蒋小三                    境内自然人           3.19%        13,969,226

易红石                    境内自然人           2.36%        10,332,616

西藏信托有限公司-西
藏信托-莱茵 2 号集合     其他                 2.21%         9,657,516
资金信托计划

蒋安明                    境内自然人           2.13%         9,304,728

蒋俊                      境内自然人           2.11%         9,205,859

财通证券资管-宁波银
行-财通证券资管莱茵 1 其他                    1.71%         7,498,703
号集合资产管理计划

                                       前 10 名无限售条件股东持股情况

                                                                                               股份种类
               股东名称                     持有无限售条件股份数量
                                                                                        股份种类          数量

梁定志                                                                   20,874,447 人民币普通股          20,874,447

中央汇金资产管理有限责任公司                                             19,491,600 人民币普通股          19,491,600

秦本军                                                                   19,210,128 人民币普通股          19,210,128

蒋小三                                                                   13,969,226 人民币普通股          13,969,226

易红石                                                                   10,332,616 人民币普通股          10,332,616

西藏信托有限公司-西藏信托-莱茵
                                                                          9,657,516 境内上市外资股         9,657,516
2 号集合资金信托计划

蒋安明                                                                    9,304,728 人民币普通股           9,304,728

蒋俊                                                                      9,205,859 人民币普通股           9,205,859


                                                                                                                       4
                                                          桂林莱茵生物科技股份有限公司 2018 年第三季度报告全文


姚新德                                                               8,590,411 人民币普通股         8,590,411

财通证券资管-宁波银行-财通证券
                                                                     7,498,703 人民币普通股         7,498,703
资管莱茵 1 号集合资产管理计划

                                   1、公司股东秦本军与蒋安明、蒋小三、蒋俊为兄弟关系,属于一致行动人。2、西
                                   藏信托有限公司-西藏信托-莱茵 2 号集合资金信托计划系公司第二期员工持股计
上述股东关联关系或一致行动的说明 划账户。3、财通证券资管—宁波银行—财通证券资管莱茵 1 号集合资产管理计划系
                                   公司第一期员工持股计划账户。4、姚新德系公司董事,与秦本军、蒋安明、蒋小三、
                                   蒋俊均不存在一致行动关系。5、其他股东之间关系不详。

前 10 名普通股股东参与融资融券业   蒋俊先生通过中信建投证券有限责任公司客户信用交易担保证券账户持有公司股票
务情况说明(如有)                 9,205,859 股。

公司前 10 名普通股股东、前 10 名无限售条件普通股股东在报告期内是否进行约定购回交易
□ 是 √ 否
公司前 10 名普通股股东、前 10 名无限售条件普通股股东在报告期内未进行约定购回交易。


2、公司优先股股东总数及前 10 名优先股股东持股情况表

□ 适用 √ 不适用




                                                                                                                5
                                                                        桂林莱茵生物科技股份有限公司 2018 年第三季度报告全文




                                                 第三节 重要事项

一、报告期主要财务数据、财务指标发生变动的情况及原因

√ 适用 □ 不适用
1、资产负债表项目变动幅度在30%以上的情况说明:

     项目               期末余额               期初余额          增减比例                          变动原因

   应收票据            1,950,000.00                              100.00%      系报告期收到银行汇票尚未到期所致

                                                                              主要系报告期 BT 项目多个单体项目验收并移交业
     存货            1,367,483,533.96      1,862,136,763.26      -26.56%
                                                                              主冲减存货所致

  长期应收款                                 16,960,000.00       -100.00%     系报告期 BT 项目已收回借款所致


   在建工程            6,976,615.21          2,053,039.26        239.82%      主要系报告期新工厂新增在建项目所致

                                                                              系报告期支付新工厂的设备款增加并从“预付账款”
其他非流动资产        13,975,675.25          2,118,126.91        559.81%
                                                                              重分类所致

   短期借款           251,484,920.00        175,000,000.00        43.71%      系报告期短期银行贷款增加所致

                                                                              主要系报告期 BT 项目多个单体项目验收并移交业
   预收款项           506,114,425.18        970,273,955.19       -47.84%
                                                                              主冲减预收款项所致

 应付职工薪酬          1,728,227.13          4,519,527.14        -61.76%      主要系报告期发放上年计提的绩效工资及奖金所致

                                                                              主要系报告期支付上年末应付企业所得税等税款所
   应交税费            3,273,621.83          42,138,774.91       -92.23%
                                                                              致

一年内到期的非                                                                主要系报告期摊销搬迁补偿等政府补助所致
                       5,166,971.34          10,445,274.68       -50.53%
   流动负债

                                                                              系报告期 BT 项目缴纳税金导致计提的税金加附加
 其他流动负债         11,718,526.45          25,870,103.27       -54.70%
                                                                              减少所致

 其他综合收益          5,791,633.50          3,546,921.01         63.29%      系报告期外币报表折算差额所致




2、利润变动表项目金额变动幅度在30%以上的情况:

    项目            本年发生额          上年发生额           增减比例                          变动原因

                                                                           主要系报告期BT项目已到收尾阶段工程量减少导致收
  营业收入       455,477,822.79        544,816,224.88         -16.40%
                                                                           入减少

  销售费用       23,653,277.36          18,152,785.30         30.30%       主要系报告期子公司扩充人员等增加费用所致

  管理费用       36,420,458.86          29,326,717.33         24.19%       主要系报告期人员工资性性费用及折旧费增加所致




                                                                                                                          6
                                                                       桂林莱茵生物科技股份有限公司 2018 年第三季度报告全文



  研发费用       10,685,925.36        6,139,112.33            74.06%       主要系报告期研发投入增加所致

                                                                           主要系报告期银行贷款减少所致
  财务费用          9,994,417.26     16,138,432.98          -38.07%

                                                                           主要系报告期计入当期政府补助增加所致
  其他收益          7,448,730.84      4,799,975.00            55.18%

                                                                           系上年增持桂林银行投资款致使分红比上年同期增加
  投资收益          9,106,763.70      6,235,754.57            46.04%
                                                                           所致
                                                                           主要系报告期对外捐赠及预计负债增加所致
 营业外支出         3,775,535.79        8,233.31          45756.84%

                                                                           主要系报告期因应纳税所得额减少所致
 所得税费用         8,632,261.30     15,712,203.04          -45.06%



3、流量表项目金额变动幅度在30%以上的情况:

          项目                 本年发生额             上年发生额            增减比例                   变动原因

                                                                                          主要系报告期BT项目收到回购资金减少
经营活动现金流量净额           9,170,852.21          376,148,592.77          -97.56%
                                                                                          及各项税费支出增加所致
                                                                                          主要系报告期新工厂建设支出、上海子公
投资活动现金流量净额          -74,917,858.76         -219,087,585.62         65.80%
                                                                                          司装修工程等支出减少所致

筹资活动现金流量净额          72,447,565.47          -112,358,089.32        164.48%       主要系报告期新增贷款净额增加所致。




二、重要事项进展情况及其影响和解决方案的分析说明

√ 适用 □ 不适用

     1、BT项目合同
    2011年8月30日,公司披露了《关于全资子公司桂林莱茵投资有限公司签订BT项目合同的公告》。莱
茵投资与湖南省建筑工程集团总公司、湖南省建工园林工程有限公司组成的联合体与桂林市临桂新区管理
委员会、桂林市临桂新区城市建设投资有限公司、桂林市大禹水利基础设施建设投资有限公司签订了《桂
林市临桂新区防洪排涝及湖塘水系工程投资、建设与移交合同书》,BT项目总投资估算约为人民币16.2亿
元,建安总投资不低于人民币13.2亿元,其余3亿元为工程建设其他费用(综合费用)。
    截至2018年9月30日,根据桂林莱茵投资有限公司估算,BT项目已累计完成工程产值约18.1亿元,累
计收到回购款13.084亿元。
     2、公司与芬美意签订了日常经营重大合同
    2018年9月12日,公司与FirmenichS.A(芬美意)签署了一份关于天然甜味剂相关产品独家分销的《商
业合同》及其附件,根据合同约定,芬美意作为公司天然甜味剂、甜味剂配方及与天然甜味剂有关的原料
在中国境外市场的独家分销商。在合同期限内,芬美意及其附属公司向公司采购产品的累计目标收入金额
为4亿美元(含税),最低累计目标收入金额为3.45亿美元。合同后续的履行将采取订单的方式。本合同的
签署将对公司未来5年业绩产生较为积极的影响,但不会对公司2018年度业绩产生重大影响。目前合同正
常履行中。


              重要事项概述                         披露日期                            临时报告披露网站查询索引

BT 项目                                  2018 年 01 月 10 日           巨潮资讯网(www.cninfo.com.cn),《BT 项目合同实施进展



                                                                                                                                7
                                                           桂林莱茵生物科技股份有限公司 2018 年第三季度报告全文


                                                          公告》(公告编号 2018- 002)。

                                                          巨潮资讯网(www.cninfo.com.cn),《BT 项目合同实施进展
                                    2018 年 04 月 09 日
                                                          公告》(公告编号 2018- 025)。

                                                          巨潮资讯网(www.cninfo.com.cn),《BT 项目合同实施进展
                                    2018 年 07 月 07 日
                                                          公告》(公告编号 2018- 042)。

                                                          巨潮资讯网(www.cninfo.com.cn),《BT 项目合同实施进展
                                    2018 年 10 月 10 日
                                                          公告》(公告编号 2018- 063)。

                                                          巨潮资讯网(www.cninfo.com.cn),《关于与芬美意签订日
公司与芬美意签订了日常经营重大合同 2018 年 09 月 14 日
                                                          常经营重大合同的公告》(公告编号 2018- 061)。




三、公司实际控制人、股东、关联方、收购人以及公司等承诺相关方在报告期内超期未履行
完毕的承诺事项

□ 适用 √ 不适用
公司报告期不存在公司实际控制人、股东、关联方、收购人以及公司等承诺相关方在报告期内超期未履行完毕的承诺事项。


四、对 2018 年度经营业绩的预计

2018 年度预计的经营业绩情况:归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形
归属于上市公司股东的净利润为正值且不属于扭亏为盈的情形

2018 年度归属于上市公司股东的净利润变动幅度                             -60%     至                        -40%

2018 年度归属于上市公司股东的净利润变动区间(万元)                  8,237.57    至                    12,356.38

2017 年度归属于上市公司股东的净利润(万元)                                                            20,593.97

                                                      主要系 2017 年公司因转让子公司股权、搬迁补偿等确认的非经
                                                      常损益金额达 1.2 亿元左右,而 2018 年预计非经常损益金额较
                                                      小,公司预计 2018 年扣非后净利润较上年实现一定增长。其中,
业绩变动的原因说明
                                                      植提业务收入预计较去年同期保持较好的增长,而 BT 项目建设
                                                      进入收尾期,工程量减少,但大部分工程报告期完成验收,预计
                                                      净利润较上年略有增长。


五、以公允价值计量的金融资产

□ 适用 √ 不适用


六、违规对外担保情况

□ 适用 √ 不适用
公司报告期无违规对外担保情况。




                                                                                                                   8
                                                        桂林莱茵生物科技股份有限公司 2018 年第三季度报告全文


七、控股股东及其关联方对上市公司的非经营性占用资金情况

□ 适用 √ 不适用
公司报告期不存在控股股东及其关联方对上市公司的非经营性占用资金。


八、委托理财

□ 适用 √ 不适用
公司报告期不存在委托理财。


九、报告期内接待调研、沟通、采访等活动登记表

□ 适用 √ 不适用
公司报告期内未发生接待调研、沟通、采访等活动。




                                                                                                          9
                                                   桂林莱茵生物科技股份有限公司 2018 年第三季度报告全文




                                         第四节 财务报表

一、财务报表

1、合并资产负债表

编制单位:桂林莱茵生物科技股份有限公司
                                                                                                 单位:元

                  项目                        期末余额                           期初余额

流动资产:

    货币资金                                               35,683,471.66                    28,460,559.33

    结算备付金

    拆出资金

    以公允价值计量且其变动计入当期
损益的金融资产

    衍生金融资产

    应收票据及应收账款                                     86,084,266.55                    75,402,772.68

      其中:应收票据                                         1,950,000.00

               应收账款                                    84,134,266.55                    75,402,772.68

    预付款项                                               20,234,128.49                    20,295,041.44

    应收保费

    应收分保账款

    应收分保合同准备金

    其他应收款                                             28,136,056.38                    29,123,154.42

    买入返售金融资产

    存货                                                 1,367,483,533.96              1,862,136,763.26

    持有待售资产

    一年内到期的非流动资产

    其他流动资产                                           32,091,480.88                    32,027,731.41

流动资产合计                                             1,569,712,937.92              2,047,446,022.54

非流动资产:

    发放贷款及垫款

    可供出售金融资产                                      179,721,550.03                 178,221,550.03

    持有至到期投资



                                                                                                       10
                                     桂林莱茵生物科技股份有限公司 2018 年第三季度报告全文


    长期应收款                                                              16,960,000.00

    长期股权投资

    投资性房地产                           5,651,687.33                      5,770,225.07

    固定资产                             549,797,531.37                    571,307,991.82

    在建工程                               6,976,615.21                      2,053,039.26

    生产性生物资产

    油气资产

    无形资产                              51,723,164.50                     52,690,792.84

    开发支出

    商誉

    长期待摊费用                             139,472.02                       453,283.93

    递延所得税资产                        19,280,170.01                     19,929,481.53

    其他非流动资产                        13,975,675.25                      2,118,126.91

非流动资产合计                           827,265,865.72                    849,504,491.39

资产总计                               2,396,978,803.64                  2,896,950,513.93

流动负债:

    短期借款                             251,484,920.00                    175,000,000.00

    向中央银行借款

    吸收存款及同业存放

    拆入资金

    以公允价值计量且其变动计入当期
损益的金融负债

    衍生金融负债

    应付票据及应付账款                   348,712,378.24                    462,938,107.77

    预收款项                             506,114,425.18                    970,273,955.19

    卖出回购金融资产款

    应付手续费及佣金

    应付职工薪酬                           1,728,227.13                      4,519,527.14

    应交税费                               3,273,621.83                     42,138,774.91

    其他应付款                            22,540,848.03                     18,665,031.92

    应付分保账款

    保险合同准备金

    代理买卖证券款

    代理承销证券款




                                                                                        11
                                              桂林莱茵生物科技股份有限公司 2018 年第三季度报告全文


    持有待售负债

    一年内到期的非流动负债                           5,166,971.34                    10,445,274.68

    其他流动负债                                   11,718,526.45                     25,870,103.27

流动负债合计                                     1,150,739,918.20                 1,709,850,774.88

非流动负债:

    长期借款

    应付债券

      其中:优先股

               永续债

    长期应付款

    长期应付职工薪酬

    预计负债                                         1,756,000.00

    递延收益                                      135,252,469.67                    134,442,469.67

    递延所得税负债                                      358,580.98                    1,638,121.47

    其他非流动负债

非流动负债合计                                    137,367,050.65                    136,080,591.14

负债合计                                         1,288,106,968.85                 1,845,931,366.02

所有者权益:

    股本                                          437,281,362.00                    437,281,362.00

    其他权益工具

      其中:优先股

               永续债

    资本公积                                      261,669,420.58                    261,669,420.58

    减:库存股

    其他综合收益                                     5,791,633.50                     3,546,921.01

    专项储备

    盈余公积                                       28,948,074.93                     28,948,074.93

    一般风险准备

    未分配利润                                    375,158,145.15                    319,543,562.80

归属于母公司所有者权益合计                       1,108,848,636.16                 1,050,989,341.32

    少数股东权益                                         23,198.63                       29,806.59

所有者权益合计                                   1,108,871,834.79                 1,051,019,147.91

负债和所有者权益总计                             2,396,978,803.64                 2,896,950,513.93


法定代表人:秦本军           主管会计工作负责人:郑辉                     会计机构负责人:张为鹏


                                                                                                12
                                            桂林莱茵生物科技股份有限公司 2018 年第三季度报告全文


2、母公司资产负债表

                                                                                          单位:元

                   项目                期末余额                           期初余额

流动资产:

    货币资金                                       20,366,915.47                     21,470,103.17

    以公允价值计量且其变动计入当期损
益的金融资产

    衍生金融资产

    应收票据及应收账款                            143,946,617.26                  106,579,108.39

      其中:应收票据                                1,950,000.00

               应收账款                           141,996,617.26                  106,579,108.39

    预付款项                                        7,694,637.73                      9,242,439.65

    其他应收款                                    200,634,446.08                  181,071,896.48

    存货                                          356,793,707.36                  399,641,874.48

    持有待售资产

    一年内到期的非流动资产

    其他流动资产                                   20,537,005.05                     21,179,289.84

流动资产合计                                      749,973,328.95                  739,184,712.01

非流动资产:

    可供出售金融资产                              179,256,481.73                  177,756,481.73

    持有至到期投资

    长期应收款

    长期股权投资                                   56,157,172.27                     55,007,172.27

    投资性房地产                                    5,651,687.33                      5,770,225.07

    固定资产                                      378,250,780.48                  395,970,781.06

    在建工程                                        6,976,615.21                      2,053,039.26

    生产性生物资产

    油气资产

    无形资产                                       51,003,064.50                     51,970,692.84

    开发支出

    商誉

    长期待摊费用

    递延所得税资产                                 19,279,969.61                     19,929,464.07

    其他非流动资产                                 13,975,675.25                      2,118,126.91



                                                                                                13
                                       桂林莱茵生物科技股份有限公司 2018 年第三季度报告全文


非流动资产合计                             710,551,446.38                    710,575,983.21

资产总计                                  1,460,524,775.33                 1,449,760,695.22

流动负债:

    短期借款                               251,484,920.00                    175,000,000.00

    以公允价值计量且其变动计入当期损
益的金融负债

    衍生金融负债

    应付票据及应付账款                      52,667,128.81                    137,969,994.89

    预收款项                                  5,734,327.20                     4,426,964.64

    应付职工薪酬                              1,352,590.67                     2,523,221.67

    应交税费                                  1,875,879.73                    35,713,025.43

    其他应付款                              21,016,225.32                     69,474,791.50

    持有待售负债

    一年内到期的非流动负债                    5,166,971.34                    10,445,274.68

    其他流动负债

流动负债合计                               339,298,043.07                    435,553,272.81

非流动负债:

    长期借款

    应付债券

      其中:优先股

               永续债

    长期应付款

    长期应付职工薪酬

    预计负债                                  1,756,000.00

    递延收益                               135,252,469.67                    134,442,469.67

    递延所得税负债                             327,230.97

    其他非流动负债

非流动负债合计                             137,335,700.64                    134,442,469.67

负债合计                                   476,633,743.71                    569,995,742.48

所有者权益:

    股本                                   437,281,362.00                    437,281,362.00

    其他权益工具

      其中:优先股

               永续债




                                                                                         14
                                        桂林莱茵生物科技股份有限公司 2018 年第三季度报告全文


    资本公积                                261,669,420.59                    261,669,420.59

    减:库存股

    其他综合收益

    专项储备

    盈余公积                                    28,948,074.93                  28,948,074.93

    未分配利润                              255,992,174.10                    151,866,095.22

所有者权益合计                              983,891,031.62                    879,764,952.74

负债和所有者权益总计                       1,460,524,775.33                 1,449,760,695.22


3、合并本报告期利润表

                                                                                      单位:元

                   项目            本期发生额                        上期发生额

一、营业总收入                                  148,297,170.58                166,463,289.70

    其中:营业收入                              148,297,170.58                166,463,289.70

          利息收入

          已赚保费

          手续费及佣金收入

二、营业总成本                                  142,523,677.10                146,336,481.38

    其中:营业成本                              109,514,314.54                122,641,409.81

          利息支出

          手续费及佣金支出

          退保金

          赔付支出净额

          提取保险合同准备金净额

          保单红利支出

          分保费用

          税金及附加                                -52,847.02                    -168,935.60

          销售费用                                8,773,119.49                    7,345,136.19

          管理费用                               13,722,218.86                 10,258,369.77

          研发费用                                6,648,192.78                    1,412,542.76

          财务费用                                3,883,479.40                    5,450,275.18

               其中:利息费用                     3,052,641.73                    5,051,512.94

                     利息收入                        22,371.24                     137,317.65

          资产减值损失                               35,199.05                    -602,316.73



                                                                                            15
                                            桂林莱茵生物科技股份有限公司 2018 年第三季度报告全文


     加:其他收益                                  1,523,160.00                     2,505,860.00

投资收益(损失以“-”号填列)                                                       613,561.24

             其中:对联营企业和合营企业的
投资收益

公允价值变动收益(损失以“-”号填列)

汇兑收益(损失以“-”号填列)

资产处置收益(损失以“-”号填列)

三、营业利润(亏损以“-”号填列)                 7,296,653.48                    23,246,229.56

     加:营业外收入                                  45,287.92                        46,776.68

     减:营业外支出                                   5,000.00

四、利润总额(亏损总额以“-”号填列)             7,336,941.40                    23,293,006.24

     减:所得税费用                                2,124,846.79                     4,500,907.19

五、净利润(净亏损以“-”号填列)                 5,212,094.61                    18,792,099.05

     (一)持续经营净利润(净亏损以“-”
                                                   5,212,094.61
号填列)

     (二)终止经营净利润(净亏损以“-”
号填列)

     归属于母公司所有者的净利润                    5,212,032.38                    18,634,102.66

     少数股东损益                                        62.23                       157,996.39

六、其他综合收益的税后净额                         2,553,863.09                      -158,290.39

  归属母公司所有者的其他综合收益的税
                                                   2,553,863.09                      -158,290.39
后净额

 (一)不能重分类进损益的其他综合收益

           1.重新计量设定受益计划变动额

  2.权益法下不能转损益的其他综合收益

     (二)将重分类进损益的其他综合收益            2,553,863.09                      -158,290.39

  1.权益法下可转损益的其他综合收益

  2.可供出售金融资产公允价值变动损益

  3.持有至到期投资重分类为可供出售金
融资产损益

  4.现金流量套期损益的有效部分

             5.外币财务报表折算差额                2,553,863.09                      -158,290.39

             6.其他

归属于少数股东的其他综合收益的税后净


七、综合收益总额                                   7,765,957.70                    18,633,808.66


                                                                                              16
                                                                桂林莱茵生物科技股份有限公司 2018 年第三季度报告全文


    归属于母公司所有者的综合收益总额                                      7,765,895.47                 18,475,812.27

    归属于少数股东的综合收益总额                                                62.23                      157,996.39

八、每股收益:

    (一)基本每股收益                                                            0.01                            0.04

    (二)稀释每股收益                                                            0.01                            0.04

本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:0 元,上期被合并方实现的净利润为:0 元。


法定代表人:秦本军                             主管会计工作负责人:郑辉                     会计机构负责人:张为鹏


4、母公司本报告期利润表

                                                                                                              单位:元

                      项目                                本期发生额                         上期发生额

一、营业收入                                                           101,574,055.78                  59,476,882.07

    减:营业成本                                                        80,528,916.58                  41,799,105.93

           税金及附加                                                                                     -623,347.53

           销售费用                                                       3,476,461.97                    4,110,020.26

           管理费用                                                       6,721,260.49                    5,085,943.98

           研发费用                                                       6,648,192.78                    1,412,542.76

           财务费用                                                       -499,807.07                     6,316,452.45

             其中:利息费用                                               3,052,641.73                    4,761,894.88

                   利息收入                                                 15,636.65                       71,232.66

           资产减值损失                                                     -77,495.54                    -481,235.94

    加:其他收益                                                          1,523,160.00                    2,505,860.00

           投资收益(损失以“-”号填列)                                                                   14,990.82

  其中:对联营企业和合营企业的投资收益

  公允价值变动收益(损失以“-”号填列)

           资产处置收益(损失以“-”号填列)

二、营业利润(亏损以“-”号填列)                                        6,299,686.57                    4,378,250.98

    加:营业外收入                                                          45,287.92                       46,776.68

    减:营业外支出                                                            5,000.00

三、利润总额(亏损总额以“-”号填列)                                    6,339,974.49                    4,425,027.66

    减:所得税费用                                                         811,047.16                      838,218.20

四、净利润(净亏损以“-”号填列)                                        5,528,927.33                    3,586,809.46

    (一)持续经营净利润(净亏损以“-”
                                                                          5,528,927.33
号填列)


                                                                                                                    17
                                                 桂林莱茵生物科技股份有限公司 2018 年第三季度报告全文


     (二)终止经营净利润(净亏损以“-”
号填列)

五、其他综合收益的税后净额

 (一)不能重分类进损益的其他综合收益

     1.重新计量设定受益计划变动额

     2.权益法下不能转损益的其他综合收


     (二)将重分类进损益的其他综合收益

     1.权益法下可转损益的其他综合收益

     2.可供出售金融资产公允价值变动损


  3.持有至到期投资重分类为可供出售金
融资产损益

  4.现金流量套期损益的有效部分

  5.外币财务报表折算差额

  6.其他

六、综合收益总额                                           5,528,927.33                    3,586,809.46

七、每股收益:

     (一)基本每股收益                                            0.01                            0.01

     (二)稀释每股收益                                            0.01                            0.01


5、合并年初到报告期末利润表

                                                                                               单位:元

                      项目                  本期发生额                        上期发生额

一、营业总收入                                           455,477,822.79                544,816,224.88

     其中:营业收入                                      455,477,822.79                544,816,224.88

             利息收入

             已赚保费

             手续费及佣金收入

二、营业总成本                                           382,257,448.70                450,136,764.94

     其中:营业成本                                      299,763,269.66                379,274,827.69

             利息支出

             手续费及佣金支出

             退保金

             赔付支出净额


                                                                                                     18
                                               桂林莱茵生物科技股份有限公司 2018 年第三季度报告全文


             提取保险合同准备金净额

             保单红利支出

             分保费用

             税金及附加                               1,591,717.06                     1,213,258.04

             销售费用                                23,653,277.36                    18,152,785.30

             管理费用                                36,420,458.86                    29,326,717.33

             研发费用                                10,685,925.36                     6,139,112.33

             财务费用                                 9,994,417.26                    16,138,432.98

               其中:利息费用                         7,325,642.50                    15,041,052.52

                     利息收入                           79,548.67                       203,288.92

             资产减值损失                              148,383.14                       -108,368.73

    加:其他收益                                      7,448,730.84                     4,799,975.00

           投资收益(损失以“-”号填列)             9,106,763.70                     6,235,754.57

其中:对联营企业和合营企业的投资收益

公允价值变动收益(损失以“-”号填列)

           汇兑收益(损失以“-”号填列)

           资产处置收益(损失以“-”号填列)

三、营业利润(亏损以“-”号填列)                   89,775,868.63                   105,715,189.51

    加:营业外收入                                     103,970.95                       130,596.34

    减:营业外支出                                    3,775,535.79                         8,233.31

四、利润总额(亏损总额以“-”号填列)               86,104,303.79                   105,837,552.54

    减:所得税费用                                    8,632,261.30                    15,712,203.04

五、净利润(净亏损以“-”号填列)                   77,472,042.49                    90,125,349.50

    (一)持续经营净利润(净亏损以“-”
                                                     77,472,042.49
号填列)

    (二)终止经营净利润(净亏损以“-”
号填列)

    归属于母公司所有者的净利润                       77,478,650.45                    89,999,361.12

    少数股东损益                                         -6,607.96                      125,988.38

六、其他综合收益的税后净额                            2,244,712.49                      -458,104.71

  归属母公司所有者的其他综合收益的税
                                                      2,244,712.49                      -458,104.71
后净额

 (一)不能重分类进损益的其他综合收益

  1.重新计量设定受益计划变动额

  2.权益法下不能转损益的其他综合收益


                                                                                                 19
                                                         桂林莱茵生物科技股份有限公司 2018 年第三季度报告全文


   (二)将重分类进损益的其他综合收益                             2,244,712.49                     -458,104.71

  1.权益法下可转损益的其他综合收益

  2.可供出售金融资产公允价值变动损益

  3.持有至到期投资重分类为可供出售金
融资产损益

  4.现金流量套期损益的有效部分

  5.外币财务报表折算差额                                          2,244,712.49                     -458,104.71

  6.其他

  归属于少数股东的其他综合收益的税后
净额

七、综合收益总额                                                 79,716,754.98                  89,667,244.79

    归属于母公司所有者的综合收益总额                             79,723,362.94                  89,541,256.41

    归属于少数股东的综合收益总额                                     -6,607.96                      125,988.38

八、每股收益:

    (一)基本每股收益                                                    0.18                             0.21

    (二)稀释每股收益                                                    0.18                             0.21

本期发生同一控制下企业合并的,被合并方在合并前实现的净利润为:0.00 元,上期被合并方实现的净利润为:0.00 元。


6、母公司年初到报告期末利润表

                                                                                                       单位:元

                      项目                         本期发生额                         上期发生额

一、营业收入                                                    274,373,812.49                 197,646,114.41

    减:营业成本                                                220,049,897.20                 143,023,121.74

           税金及附加                                             1,001,161.33                       -94,264.23

           销售费用                                               7,291,874.27                     9,009,312.91

           管理费用                                              19,145,275.62                  18,080,721.42

           研发费用                                              10,685,925.36                     6,139,112.33

           财务费用                                               3,942,434.66                  16,337,638.95

             其中:利息费用                                       7,325,642.50                  12,640,323.34

                   利息收入                                          54,644.40                      119,430.82

           资产减值损失                                             -15,115.54                       -28,214.20

    加:其他收益                                                  7,443,496.84                     4,799,975.00

           投资收益(损失以“-”号填列)                       109,106,763.70                     5,637,184.15

  其中:对联营企业和合营企业的投资收益

           公允价值变动收益(损失以“-”


                                                                                                             20
                                                    桂林莱茵生物科技股份有限公司 2018 年第三季度报告全文


号填列)

           资产处置收益(损失以“-”号填列)

二、营业利润(亏损以“-”号填列)                          128,822,620.13                 15,615,844.64

    加:营业外收入                                             103,970.95                       91,071.54

    减:营业外支出                                            1,769,763.04                       8,233.31

三、利润总额(亏损总额以“-”号填列)                      127,156,828.04                 15,698,682.87

    减:所得税费用                                            1,166,681.06                    1,729,954.90

四、净利润(净亏损以“-”号填列)                          125,990,146.98                 13,968,727.97

    (一)持续经营净利润(净亏损以“-”
                                                            125,990,146.98
号填列)

    (二)终止经营净利润(净亏损以“-”
号填列)

五、其他综合收益的税后净额

 (一)不能重分类进损益的其他综合收益

  1.重新计量设定受益计划变动额

  2.权益法下不能转损益的其他综合收益

   (二)将重分类进损益的其他综合收益

  1.权益法下可转损益的其他综合收益

  2.可供出售金融资产公允价值变动损益

  3.持有至到期投资重分类为可供出售金
融资产损益

  4.现金流量套期损益的有效部分

  5.外币财务报表折算差额

  6.其他

六、综合收益总额                                            125,990,146.98                 13,968,727.97

七、每股收益:

    (一)基本每股收益                                                0.29                            0.03

    (二)稀释每股收益                                                0.29                            0.03


7、合并年初到报告期末现金流量表

                                                                                                  单位:元

                    项目                       本期发生额                        上期发生额

一、经营活动产生的现金流量:

    销售商品、提供劳务收到的现金                            467,468,173.81                840,438,242.76

  客户存款和同业存放款项净增加额


                                                                                                        21
                                         桂林莱茵生物科技股份有限公司 2018 年第三季度报告全文


    向中央银行借款净增加额

  向其他金融机构拆入资金净增加额

    收到原保险合同保费取得的现金

    收到再保险业务现金净额

    保户储金及投资款净增加额

    处置以公允价值计量且其变动计入当
期损益的金融资产净增加额

    收取利息、手续费及佣金的现金

    拆入资金净增加额

    回购业务资金净增加额

    收到的税费返还                             22,289,219.27                    18,495,394.09

    收到其他与经营活动有关的现金                3,613,732.23                     5,800,347.78

经营活动现金流入小计                          493,371,125.31                   864,733,984.63

    购买商品、接受劳务支付的现金              318,192,754.32                   387,933,205.51

    客户贷款及垫款净增加额

  存放中央银行和同业款项净增加额

    支付原保险合同赔付款项的现金

    支付利息、手续费及佣金的现金

    支付保单红利的现金

  支付给职工以及为职工支付的现金               45,576,885.57                    42,821,355.48

    支付的各项税费                             66,618,584.87                    20,057,535.87

    支付其他与经营活动有关的现金               53,812,048.34                    37,773,295.00

经营活动现金流出小计                          484,200,273.10                   488,585,391.86

经营活动产生的现金流量净额                      9,170,852.21                   376,148,592.77

二、投资活动产生的现金流量:

    收回投资收到的现金

    取得投资收益收到的现金                       330,740.10                       356,579.17

    处置固定资产、无形资产和其他长期资
                                                                                    70,000.00
产收回的现金净额

    处置子公司及其他营业单位收到的现
                                                                                10,014,990.82
金净额

    收到其他与投资活动有关的现金                 810,000.00                      4,000,000.00

投资活动现金流入小计                            1,140,740.10                    14,441,569.99

    购建固定资产、无形资产和其他长期资
                                               74,558,598.86                   130,313,517.61
产支付的现金



                                                                                           22
                                              桂林莱茵生物科技股份有限公司 2018 年第三季度报告全文


    投资支付的现金                                      1,500,000.00                103,215,638.00

    质押贷款净增加额

    取得子公司及其他营业单位支付的现
金净额

    支付其他与投资活动有关的现金

投资活动现金流出小计                                   76,058,598.86                233,529,155.61

投资活动产生的现金流量净额                            -74,917,858.76               -219,087,585.62

三、筹资活动产生的现金流量:

    吸收投资收到的现金

其中:子公司吸收少数股东投资收到的现金

    取得借款收到的现金                                276,333,780.00                515,000,000.00

    发行债券收到的现金

    收到其他与筹资活动有关的现金                       58,399,553.89                298,312,000.00

筹资活动现金流入小计                                  334,733,333.89                813,312,000.00

    偿还债务支付的现金                                203,734,760.00                605,000,000.00

    分配股利、利润或偿付利息支付的现金                 28,551,008.42                 21,658,089.32

其中:子公司支付给少数股东的股利、利润

    支付其他与筹资活动有关的现金                       30,000,000.00                299,012,000.00

筹资活动现金流出小计                                  262,285,768.42                925,670,089.32

筹资活动产生的现金流量净额                             72,447,565.47               -112,358,089.32

四、汇率变动对现金及现金等价物的影响                     532,353.41                      118,937.68

五、现金及现金等价物净增加额                            7,232,912.33                 44,821,855.51

    加:期初现金及现金等价物余额                       28,363,535.31                 28,701,432.22

六、期末现金及现金等价物余额                           35,596,447.64                 73,523,287.73


8、母公司年初到报告期末现金流量表

                                                                                            单位:元

                项目                     本期发生额                        上期发生额

一、经营活动产生的现金流量:

    销售商品、提供劳务收到的现金                      260,075,025.35                221,580,078.83

    收到的税费返还                                     22,289,219.27                 18,495,394.09

    收到其他与经营活动有关的现金                        2,522,437.21                    4,444,663.92

经营活动现金流入小计                                  284,886,681.83                244,520,136.84

    购买商品、接受劳务支付的现金                      198,819,874.46                155,551,070.12



                                                                                                  23
                                         桂林莱茵生物科技股份有限公司 2018 年第三季度报告全文


    支付给职工以及为职工支付的现金             31,390,450.63                    32,401,866.81

    支付的各项税费                             35,370,509.80                     3,391,366.16

    支付其他与经营活动有关的现金               29,546,890.23                    23,425,397.75

经营活动现金流出小计                          295,127,725.12                   214,769,700.84

经营活动产生的现金流量净额                    -10,241,043.29                    29,750,436.00

二、投资活动产生的现金流量:

    收回投资收到的现金

    取得投资收益收到的现金                       330,740.10                       356,579.17

    处置固定资产、无形资产和其他长期资
                                                                                    70,000.00
产收回的现金净额

    处置子公司及其他营业单位收到的现
                                                                                10,014,990.82
金净额

    收到其他与投资活动有关的现金                 810,000.00                      4,000,000.00

投资活动现金流入小计                            1,140,740.10                    14,441,569.99

    购建固定资产、无形资产和其他长期资
                                               70,241,704.71                   112,396,544.88
产支付的现金

    投资支付的现金                              2,650,000.00                   106,401,048.00

    取得子公司及其他营业单位支付的现
金净额

    支付其他与投资活动有关的现金

投资活动现金流出小计                           72,891,704.71                   218,797,592.88

投资活动产生的现金流量净额                    -71,750,964.61                  -204,356,022.89

三、筹资活动产生的现金流量:

    吸收投资收到的现金

    取得借款收到的现金                        276,333,780.00                   485,000,000.00

    发行债券收到的现金

    收到其他与筹资活动有关的现金              133,000,000.00                   383,000,000.00

筹资活动现金流入小计                          409,333,780.00                   868,000,000.00

    偿还债务支付的现金                        203,734,760.00                   545,000,000.00

    分配股利、利润或偿付利息支付的现金         28,551,008.42                    13,681,706.01

    支付其他与筹资活动有关的现金               96,230,000.00                   133,497,031.42

筹资活动现金流出小计                          328,515,768.42                   692,178,737.43

筹资活动产生的现金流量净额                     80,818,011.58                   175,821,262.57

四、汇率变动对现金及现金等价物的影响               80,808.62                        -8,480.48

五、现金及现金等价物净增加额                   -1,093,187.70                     1,207,195.20



                                                                                           24
                                    桂林莱茵生物科技股份有限公司 2018 年第三季度报告全文


     加:期初现金及现金等价物余额         21,379,079.15                    24,622,742.16

六、期末现金及现金等价物余额              20,285,891.45                    25,829,937.36


二、审计报告

第三季度报告是否经过审计
□ 是 √ 否
公司第三季度报告未经审计。




                                                                                      25
桂林莱茵生物科技股份有限公司 2018 年第三季度报告全文



             桂林莱茵生物科技股份有限公司




             法定代表人:

                                     秦本军

                                2018 年    月    日




                                                 26
数据加载中...
prevnext
手机查看股票